Predictors of biologic disease modifying antirheumatic drugs withdrawal due to the development of adverse events in patients with rheumatoid arthritis
Currently, a large number of highly effective biologic disease modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) are used for the treatment of rheumatoid arthritis (RA). However, in addition to effectiveness, it is necessary to evaluate the risk of adverse events (AEs)...
| Asıl Yazarlar: | , , , , |
|---|---|
| Materyal Türü: | Makale |
| Dil: | Russian |
| Baskı/Yayın Bilgisi: |
IMA-PRESS LLC
2022-12-01
|
| Seri Bilgileri: | Современная ревматология |
| Konular: | |
| Online Erişim: | https://mrj.ima-press.net/mrj/article/view/1368 |